Cargando…
The efficacy and safety of riluzole for neurodegenerative movement disorders: a systematic review with meta-analysis
Neurodegenerative movement disorders mainly include Parkinson’s disease, atypical parkinsonisms, Huntington disease, and hereditary ataxia. Riluzole is the only drug approved by the US Food and Drug Administration for amyotrophic lateral sclerosis. The neuroprotective effects of riluzole have been o...
Autores principales: | Liu, Jia, Wang, Lu-Ning |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058579/ https://www.ncbi.nlm.nih.gov/pubmed/29226728 http://dx.doi.org/10.1080/10717544.2017.1413446 |
Ejemplares similares
-
Lack of riluzole efficacy in the progression of the neurodegenerative phenotype in a new conditional mouse model of striatal degeneration
por: Kreiner, Grzegorz, et al.
Publicado: (2017) -
Effects of riluzole on psychiatric disorders with anxiety or fear as primary symptoms: A systematic review
por: Kawashima, Yoshitaka, et al.
Publicado: (2023) -
Pharmacokinetics, Bioavailability, and Swallowing Safety With Riluzole Oral Film
por: Wymer, James, et al.
Publicado: (2022) -
Use of Riluzole for the Treatment of Hereditary Ataxias: A Systematic Review
por: Ayala, Iván Nicolas, et al.
Publicado: (2022) -
A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders
por: Lim, Keane, et al.
Publicado: (2017)